The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
Cell cycle proteins as promising targets in cancer therapy
Open accessAbstract
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant activity of various cell cycle proteins. Therefore, cell cycle regulators are considered attractive targets in cancer therapy. Intriguingly, animal models demonstrate that some of these proteins are not essential for proliferation of non-transformed cells and development of most tissues. By contrast, many cancers are uniquely dependent on these proteins and hence are selectively sensitive to their inhibition. After decades of research on the physiological functions of cell cycle proteins and their relevance for cancer, this knowledge recently translated into the first approved cancer therapeutic targeting of a direct regulator of the cell cycle. In this Review, we focus on proteins that directly regulate cell cycle progression (such as cyclin-dependent kinases (CDKs)), as well as checkpoint kinases, Aurora kinases and Polo-like kinases (PLKs). We discuss the role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment and results of clinical trials, as well as the future therapeutic potential of various cell cycle inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.”
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to Mitosis
Gavet, O., & Pines, J. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.02.013 · Cited by 844
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190030497 · Cited by 829
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCF Fbw7 Ubiquitin Ligase
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065203 · Cited by 762
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710
Mueller, P. R., Coleman, T. R., Kumagai, A., & Dunphy, W. G. (1995) · Science · doi:10.1126/science.270.5233.86 · Cited by 695
Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication
Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P.-K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00093-3 · Cited by 685
Meraldi, P. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.483 · Cited by 658
Anand, S., Penrhyn-Lowe, S., & Venkitaraman, A. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00235-0 · Cited by 631
Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems
Liu, M., Pereira, F. A., Price, S. D., Chu, M.-J., Shope, C., Himes, D., Eatock, R. A., Brownell, W. E., Lysakowski, A., & Tsai, M.-J. (2000) · Genes & Development · doi:10.1101/gad.840500 · Cited by 625
Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry
Seki, A., Coppinger, J. A., Jang, C.-Y., Yates, J. R., & Fang, G. (2008) · Science · doi:10.1126/science.1157425 · Cited by 619
Strohmaier, H., Spruck, C. H., Kaiser, P., Won, K.-A., Sangfelt, O., & Reed, S. I. (2001) · Nature · doi:10.1038/35095076 · Cited by 583
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573
Self-citationDinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Skp2 is oncogenic and overexpressed in human cancers
Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., & Krek, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081474898 · Cited by 505
CDC25 Phosphatases as Potential Human Oncogenes
Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., & Beach, D. (1995) · Science · doi:10.1126/science.7667636 · Cited by 504
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
O'Connell, M. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.545 · Cited by 398
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Diril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385
Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells
van Vugt, M. A. T. M., Brás, A., & Medema, R. H. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.015 · Cited by 385
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., Wang, J., Qin, J., Chow, L. T., & Harper, J. W. (2000) · Genes & Development · doi:10.1101/gad.829500 · Cited by 372
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.
Martín‐Caballero, J., Flores, J. M., García, P., & Serrano, M. (2001) · PubMed · Cited by 353
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Requirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicinska, E., Aifantis, I., Le Cam, L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 340
Self-citationWyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H. J., Altmannsberger, H.-M., Rübsamen-Waigmann, H., & Strebhardt, K. (1997) · Oncogene · doi:10.1038/sj.onc.1200862 · Cited by 323
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma
Jeng, Y.-M., Peng, S.-Y., Lin, C.-Y., & Hsu, H.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1057-03 · Cited by 304
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Manfredi, M. G., Ecsedy, J. A., Chakravarty, A., Silverman, L., Zhang, M., Hoar, K. M., Stroud, S. G., Chen, W., Shinde, V., Huck, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1536 · Cited by 300
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 299
Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Görgün, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259523 · Cited by 274
hCDC4 gene mutations in endometrial cancer.
Spruck, C., Strohmaier, H. M., Sangfelt, O., Müller, H. M., Hubalek, M., Müller‐Holzner, E., Marth, C., Widschwendter, M., & Reed, S. I. (2002) · PubMed · Cited by 268
Wang, X., Zhou, Y.-X., Qiao, W., Tominaga, Y., Ouchi, M., Ouchi, T., & Deng, C.-X. (2006) · Oncogene · doi:10.1038/sj.onc.1209707 · Cited by 261
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Melichar, B., Adenis, A., Lockhart, A. C., Bennouna, J., Dees, E. C., Kayaleh, O., Obermannova, R., DeMichele, A., Zatloukal, P., Zhang, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70051-3 · Cited by 254
Kumar, S. K., LaPlant, B., Chng, W. J., Zonder, J., Callander, N., Fonseca, R., Fruth, B., Roy, V., Erlichman, C., & Stewart, A. K. (2015) · Blood · doi:10.1182/blood-2014-05-573741 · Cited by 252
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner, S., Doni, M., Hydbring, P., Verrecchia, A., Bianchi, L., Sardella, D., Schleker, T., Perna, D., Tronnersjö, S., Murga, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2004 · Cited by 251
Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 249
Induction of Mammary Gland Hyperplasia and Carcinomas in Transgenic Mice Expressing Human Cyclin E
Bortner, D. M., & Rosenberg, M. P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.453 · Cited by 245
Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., et al. (1998) · PubMed · doi:10.1182/blood.v91.7.2482 · Cited by 240
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., & Strebhardt, K. (1999) · PubMed · Cited by 232
Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A., Brandwein, J. M., Lepretre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 231
Xu, J., Li, Y., Wang, F., Wang, X., Cheng, B., Ye, F., Xie, X., Zhou, C., & Lu, W. (2013) · Oncogene · doi:10.1038/onc.2012.121 · Cited by 227
Maris, J. M., Morton, C. L., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Keir, S. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22430 · Cited by 226
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6944 · Cited by 222
Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells
Marumoto, T., Hirota, T., Morisaki, T., Kunitoku, N., Zhang, D., Ichikawa, Y., Sasayama, T., Kuninaka, S., Mimori, T., Tamaki, N., et al. (2002) · Genes to Cells · doi:10.1046/j.1365-2443.2002.00592.x · Cited by 218
Robles, A. I., Rodriguez-Puebla, M. L., Glick, A. B., Trempus, C., Hansen, L., Sicinski, P., Tennant, R. W., Weinberg, R. A., Yuspa, S. H., & Conti, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.16.2469 · Cited by 217
Self-citationRoshak, A. K., Capper, E. A., Imburgia, C., Fornwald, J., Scott, G., & Marshall, L. A. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00080-2 · Cited by 215
Friedberg, J. W., Mahadevan, D., Cebula, E., Persky, D., Lossos, I., Agarwal, A. B., Jung, J., Burack, R., Zhou, X., Leonard, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8793 · Cited by 212
Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Cyclins and Cyclin–Dependent Kinases: Comparative Study of Hepatocellular Carcinoma Versus Cirrhosis
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50112 · Cited by 207
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis
Ko, M. A., Rosario, C. O., Hudson, J. W., Kulkarni, S., Pollett, A., Dennis, J. W., & Swallow, C. J. (2005) · Nature Genetics · doi:10.1038/ng1605 · Cited by 204
Mason, J. M., Lin, D. C.-C., Wei, X., Che, Y., Yao, Y., Kiarash, R., Cescon, D. W., Fletcher, G. C., Awrey, D. E., Bray, M. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.006 · Cited by 199
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
King, C., Diaz, H. B., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D., & Marshall, M. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1037 · Cited by 187
Daud, A. I., Ashworth, M. T., Strosberg, J., Goldman, J. W., Mendelson, D., Springett, G., Venook, A. P., Loechner, S., Rosen, L. S., Shanahan, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5027 · Cited by 185
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice.
Deane, N. G., Parker, M. A., Aramandla, R., Diehl, L., Lee, W. J., Washington, M. K., Nanney, L., Shyr, Y., & Beauchamp, R. D. (2001) · PubMed · Cited by 180
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., Hirsch, H. A., Feldman, I., Benita, Y., Toniatti, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0025 · Cited by 172
Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0928 · Cited by 171
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
p27/Kip1 mutation found in breast cancer.
Spirin, K. S., Simpson, J., Takeuchi, S., Kawamata, N., Cw, M., & Koeffler, H. P. (1996) · PubMed · Cited by 165
Invasive melanoma in Cdk4-targeted mice
Sotillo, R., García, J. F., Ortega, S., Martín, J., Dubus, P., Barbacid, M., & Malumbres, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241338598 · Cited by 164
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Cyclin B2 and p53 control proper timing of centrosome separation
Nam, H.-J., & van Deursen, J. M. (2014) · Nature Cell Biology · doi:10.1038/ncb2952 · Cited by 161
Hulit, J., Wang, C., Li, Z., Albanese, C., Rao, M., Vizio, D. D., Shah, S., Byers, S. W., Mahmood, R., Augenlicht, L. H., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7598-7611.2004 · Cited by 160
Dees, E. C., Cohen, R. B., von Mehren, M., Stinchcombe, T. E., Liu, H., Venkatakrishnan, K., Manfredi, M. G., Fingert, H. J., Burris, H. A., & Infante, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0589 · Cited by 159
Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
Karnak, D. M., Engelke, C. G., Parsels, L. A., Kausar, T., Wei, D., Robertson, J. R., Marsh, K. B., Davis, M. A., Zhao, L., Maybaum, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1038 · Cited by 158
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
Corcoran, M., Mould, S., Orchard, J., Ibbotson, R., Chapman, R., Boright, A. P., Platt, C., Tsui, L.-C., Scherer, S. W., & Oscier, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203033 · Cited by 153
Menoyo, A., Alazzouzi, H., Espín, E., Armengol, M., Yamamoto, H., & Schwartz, S. (2001) · PubMed · Cited by 151
Verlinden, L., Bempt, I. V., Eelen, G., Drijkoningen, M., Verlinden, I., Marchal, K., Wolf‐Peeters, C. D., Christiaens, M.-R., Michiels, L., Bouillon, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3545 · Cited by 149
Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression
Lu, L., Wood, J. L., Minter‐Dykhouse, K., Ye, L., Saunders, T. L., Yu, X., & Chen, J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00392-08 · Cited by 148
Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K. R., Slipicevic, A., & Flørenes, V. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038254 · Cited by 144
Gregory, G. P., Hogg, S. J., Kats, L. M., Vidacs, E., Baker, A. J., Gilan, O., Lefebure, M., Martin, B. P., Dawson, M. A., Johnstone, R. W., et al. (2014) · Leukemia · doi:10.1038/leu.2015.10 · Cited by 143
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 138
Goh, K. C., Novotny-Diermayr, V, Hart, S., Ong, L. C., Loh, Y. K., Cheong, A., Tan, Y. C., Hu, C., Jayaraman, R., William, A. D., et al. (2012) · Leukemia · doi:10.1038/leu.2011.218 · Cited by 135
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134
Fletcher, G. C., Brokx, R. D., Denny, T. A., Hembrough, T., Plum, S. M., Fogler, W. E., Sidor, C. F., & Bray, M. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0574 · Cited by 134
Matulonis, U. A., Sharma, S. K., Ghamande, S., Gordon, M. S., Prete, S. A. D., Ray-Coquard, I. L., Kutarska, E., Liu, H., Fingert, H. J., Zhou, X., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.040 · Cited by 133
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
DuBois, S. G., Marachelian, A., Fox, E., Kudgus, R. A., Reid, J. M., Groshen, S. G., Malvar, J., Bagatell, R., Wagner, L. M., Maris, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.4889 · Cited by 132
Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma
Gladden, A. B., Woolery, R., Aggarwal, P., Wasik, M. A., & Diehl, J. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209147 · Cited by 131
Brasca, M. G., Amboldi, N., Ballinari, D., Cameron, A. D., Casale, E., Cervi, G., Colombo, M., Colotta, F., Croci, V., D’Alessio, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9006559 · Cited by 130
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
Russell, M. R., Levin, K., Rader, J., Belcastro, L. T., Li, Y., Martínez, D., Pawel, B., Shumway, S. D., Maris, J. M., & Cole, K. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2669 · Cited by 130
Linden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9009 · Cited by 129
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 129
Payton, M. N., Bush, T. L., Chung, G., Ziegler, B., Eden, P., McElroy, P. L., Ross, S. L., Cee, V. J., Deak, H. L., Hodous, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3001 · Cited by 128
Montano, R. E., Chung, I., Garner, K. M., Parry, D., & Eastman, A. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0406 · Cited by 128
Takemasa, I., Yamamoto, H., Sekimoto, M., Ohue, M., Noura, S., Miyake, Y., Matsumoto, T., Aihara, T., Tomita, N., Tamaki, Y., et al. (2000) · PubMed · Cited by 126
Yang, Y., Bai, J., Shen, R. Z., Brown, S. A. N., Komissarova, E. V., Huang, Y., Jiang, N., Alberts, G. F., Costa, M., Luo, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6182 · Cited by 126
Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines
Simizu, S., & Osada, H. (2000) · Nature Cell Biology · doi:10.1038/35041102 · Cited by 124
Targeting Wee1 for the treatment of pediatric high-grade gliomas
Mueller, S., Hashizume, R., Yang, X., Kolkowitz, I., Olow, A., Phillips, J. J., Smirnov, I. V., Tom, M. W., Prados, M. D., James, C. D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not220 · Cited by 124
Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.
Gopinathan, L., Tan, S. L. W., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3440 · Cited by 123
Feldmann, G., Mishra, A., Bisht, S., Karikari, C. A., Garrido‐Laguna, I., Rasheed, Z. A., Ottenhof, N. A., Dadon, T., Alvarez, H., Fendrich, V., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.7.16475 · Cited by 123
Flynn, J. M., Jones, J. A., Johnson, A. J., Andritsos, L. A., Maddocks, K. J., Jaglowski, S. M., Hessler, J. D., Grever, M. R., Im, E., Zhou, H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.31 · Cited by 123
An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation
Lopez-Contreras, A. J., Gutierrez‐Martinez, P., Specks, J., Rodrigo-Perez, S., & Fernández-Capetillo, Ó. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112147 · Cited by 123
Karp, J. E., Thomas, B. M., Greer, J. M., Sorge, C. L., Gore, S. D., Pratz, K. W., Smith, B. D., Flatten, K. S., Peterson, K., Schneider, P. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2442 · Cited by 123
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 119
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
Michalides, R. J. A. M., van Tinteren, H., Balkenende, A., Vermorken, J. B., Benraadt, J., Huldij, J. C., & van Diest, P. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600072 · Cited by 115
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
Fernández‐Miranda, G., Trakala, M., Martin, J. J., Escobar, B., González‐Loyola, A., Ghyselinck, N. B., Ortega, S., Cañamero, M., de Castro, I. P., & Malumbres, M. (2011) · Development · doi:10.1242/dev.066381 · Cited by 114
Aurora B Overexpression Causes Aneuploidy and p21 Cip1 Repression during Tumor Development
González‐Loyola, A., Fernández‐Miranda, G., Trakala, M., Partida, D., Samejima, K., Ogawa, H., Cañamero, M., Martino, A. D., Martínez‐Ramírez, Á., de Cárcer, G., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01286-14 · Cited by 113
Barr, P. M., Li, H., Spier, C. M., Mahadevan, D., LeBlanc, M. L., Haq, M. U., Huber, B. D., Flowers, C. R., Wagner‐Johnston, N. D., Horwitz, S. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.6327 · Cited by 113
A mouse model for cyclin E-dependent genetic instability and tumorigenesis
Loeb, K. R., Kostner, H., Firpo, E. J., Norwood, T. H., Tsuchiya, K. D., Clurman, B. E., & Roberts, J. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.010 · Cited by 111
Aurora A Is Essential for Early Embryonic Development and Tumor Suppression
Lu, L., Wood, J. L., Ye, L., Minter‐Dykhouse, K., Saunders, T. L., Yu, X., & Chen, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805880200 · Cited by 111
Chao, Y., Shih, Y., Chiu, J., Chau, G. Y., Lui, W., Yang, W. K., Lee, S., & Huang, T. (1998) · PubMed · Cited by 110
Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss
Tsikitis, M., Zhang, Z., Edelmann, W., Zagzag, D., & Kalpana, G. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505300102 · Cited by 109
Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B. D., Cowley, G. S., Vázquez, F., Weir, B. A., Tsherniak, A., Parasuraman, S., Kim, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4903 · Cited by 108
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
Stadler, W. M., Vaughn, D. J., Sonpavde, G., Vogelzang, N. J., Tagawa, S. T., Petrylak, D. P., Rosen, P. J., Lin, C., Mahoney, J. F., Modi, S., et al. (2013) · Cancer · doi:10.1002/cncr.28519 · Cited by 106
Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125849 · Cited by 105
Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. W., Kelly, Y. F., Misra, R. N., Hunt, J. T., Kimball, S. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000231g · Cited by 104
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Olanich, M. E., Sun, W., Hewitt, S. M., Abdullaev, Z., Pack, S., & Barr, F. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2955 · Cited by 102
Sehdev, V., Peng, D., Soutto, M., Washington, M. K., Revetta, F. L., Ecsedy, J., Zaika, A. I., Rau, T. T., Schneider‐Stock, R., Belkhiri, A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0623 · Cited by 101
Stephenson, J., Nemunaitis, J. J., Joy, A. A., Martin, J., Jou, Y., Zhang, D., Statkevich, P., Yao, S., Zhu, Y., Zhou, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.020 · Cited by 101
Lack of Cyclin-Dependent Kinase 4 Inhibits c- myc Tumorigenic Activities in Epithelial Tissues
de Marval, P. L. M., Macias, E., Rounbehler, R. J., Siciński, P., Kiyokawa, H., Johnson, D. G., Conti, C. J., & Rodríguez‐Puebla, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7538-7547.2004 · Cited by 101
Logan, J. E., Mostofizadeh, N., Desai, A. J., von Euw, E., Conklin, D. F., Konkankit, V., Hamidi, H., Eckardt, M. A., Anderson, L. A., Chen, H., et al. (2013) · PubMed · Cited by 101
Cole, A. M., Myant, K., Reed, K. R., Ridgway, R. A., Athineos, D., van den Brink, G. R., Muncan, V., Clevers, H. C., Clarke, A. R., Siciński, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0315 · Cited by 100
Saab, R. H., Bills, J. L., Miceli, A. P., Anderson, C., Khoury, J. D., Fry, D. W., Navid, F., Houghton, P. J., & Skapek, S. X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0383 · Cited by 96
Broggini, M., Buraggi, G., Brenna, A., Riva, L., Codegoni, A. M., Torri, V., Lissoni, A. A., Mangioni, C., & D’Incalci, M. (2001) · PubMed · Cited by 92
Kemp, Z., Rowan, A., Chambers, W. M., Wortham, N. C., Halford, S. E. R., Sieber, O. M., Mortensen, N., Herbay, A. V., Gunther, T., Ilyas, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2565 · Cited by 90
Gojo, I., Sadowska, M., Walker, A., Feldman, E. J., Iyer, S. P., Baer, M. R., Sausville, E. A., Lapidus, R. G., Zhang, D., Zhu, Y., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2249-z · Cited by 88
Qi, W., Cooke, L. S., Liu, X., Rimsza, L. M., Roe, D. J., Persky, A. M. D. O., Miller, T. P., & Mahadevan, D. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.017 · Cited by 87
Zhou, L., Zhang, Y., Chen, S., Kmieciak, M., Leng, Y., Lin, H., Rizzo, K., Dumur, C. I., Ferreira‐Gonzalez, A., Dai, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2014.296 · Cited by 85
Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice
Ray, D., Terao, Y., Nimbalkar, D., Hirai, H., Osmundson, E. C., Zou, X., Franks, R. R., Christov, K. T., & Kiyokawa, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4815 · Cited by 83
Cited by
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Metadata
- Authors
- Otto, T., & Sicinski, P.
- Venue
- Nature Reviews Cancer
- Published
- 2017-01-27
- Volume
- 17
- Issue
- 2
- Pages
- 93-115
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2581841075
- Cited by
- 1,858
- References
- 288
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.